Codagenix, Inc.

Codagenix, Inc. is a biopharmaceutical company based in the US that specializes in developing live-attenuated vaccines and viral therapeutics using an innovative synthetic biology platform. Founded in 2011 and headquartered in New York, US, Codagenix, Inc. focuses on designing vaccines and therapeutics that leverage codon deoptimization technology.

The company has successfully completed 5 funding deals, with the most recent being a Series B round in February 2023, raising USD 25. 00 mn led by Serum Institute of India Pvt. Ltd. , with participation from Adjuvant Capital and Euclidean Capital.

The founders, J Coleman and Steffen Mueller, have extensive backgrounds in biotechnology, contributing to the company's strategic direction and growth. Codagenix, Inc. specializes in the development of live-attenuated vaccines and viral therapeutics, utilizing a proprietary synthetic biology platform that incorporates codon deoptimization technology. This innovative approach enables the design of precise and stable edits in viral genomes, resulting in products that provide the broad immunity benefits typically associated with live viruses while ensuring enhanced safety, efficacy, and scalability.

Codagenix's offerings target infectious diseases and cancer, aiming to address significant global health challenges. The company focuses on delivering timely vaccine solutions and novel cancer therapies through its comprehensive pipelines, which are designed for diverse applications across human health and animal health sectors. Codagenix engages clients and end-users including healthcare providers, research institutions, and veterinary services primarily within North America and Europe, expanding its reach into global markets as its products advance. Codagenix generates revenue through partnerships and collaborations with various stakeholders in the healthcare and biotechnology fields.

The company's business model includes B2B transactions, where they work closely with pharmaceutical companies, research institutions, and animal health organizations to develop and commercialize their vaccine and therapeutic solutions. Revenue is derived from joint development agreements, milestone payments, and potential royalties from successful product commercialization. Specific pricing plans and transaction structures are tailored to each partnership, reflecting the bespoke nature of the products being developed. Codagenix's focus on flagship products related to infectious diseases and cancer therapies positions it for ongoing engagement with its client base, facilitating sustained revenue streams as they progress through clinical development phases.

In February 2023, Codagenix, Inc. raised USD 25. 00 mn in Series B funding, which will support the development of the Phase 1 study for CodaVax™-H1N1 and the expansion of the oncology program to new indications. The company aims to launch new products targeting infectious diseases and explore new therapeutic avenues in oncology.

Additionally, Codagenix plans to expand its market presence in Europe and Asia by the end of 2024, broadening access to its innovative vaccine and therapeutic portfolio.